MYGN
NASDAQ · Biotechnology
Myriad Genetics Inc
$6.29
+0.27 (+4.49%)
Open$6.41
Previous Close$6.02
Day High$6.75
Day Low$6.04
52W High$8.38
52W Low$2.74
Volume—
Avg Volume4.60M
Market Cap623.16M
P/E Ratio—
EPS$-1.20
SectorBiotechnology
Analyst Ratings
Sell
15 analysts
Price Target
+558.8% upside
Current
$6.29
$6.29
Target
$41.44
$41.44
$29.39
$41.44 avg
$63.29
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 871.04M | 816.19M | 74.53M |
| Net Income | -386,553,303 | -325,991,353 | -15,758,896 |
| Profit Margin | -44.4% | -42.2% | -21.1% |
| EBITDA | -352,323,663 | -313,631,446 | -16,042,014 |
| Free Cash Flow | — | — | -13,316,178 |
| Rev Growth | +6.7% | +6.7% | +5.3% |
| Debt/Equity | 0.33 | 0.33 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |